Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

NCT06132035 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
45
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Caregen Co. Ltd.

Collaborators